Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Impact of Omitting Contralateral Systematic Biopsy on the Surgical Planning of Patients with a Unilateral Suspicious Lesion on Magnetic Resonance Imaging Undergoing Robot-assisted Radical Prostatectomy for Prostate Cancer.
van den Kroonenberg DL, Stoter JD, Jager A, Veerman H, Hagens MJ, Schoots IG, Postema AW, Hoekstra RJ, Oprea-Lager DE, Nieuwenhuijzen JA, van Leeuwen PJ, Vis AN. van den Kroonenberg DL, et al. Among authors: van leeuwen pj. Eur Urol Open Sci. 2024 Mar 21;63:13-18. doi: 10.1016/j.euros.2024.03.006. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38558763 Free PMC article.
Real-Time Identification of Nodal Metastases With 99m Tc-Prostate-Specific Membrane Antigen-Based Radioguidance and Indocyanine Green Fluorescence Imaging in Primary Prostate Cancer Surgery-On the Road to Hybrid Image-Guided Surgery.
de Barros HA, van Oosterom MN, van Leeuwen FWB, van der Poel HG, van Leeuwen PJ. de Barros HA, et al. Among authors: van leeuwen fwb, van oosterom mn, van leeuwen pj, van der poel hg. Clin Nucl Med. 2023 Aug 1;48(8):697-698. doi: 10.1097/RLU.0000000000004702. Epub 2023 Jun 10. Clin Nucl Med. 2023. PMID: 37220246
Screening and prostate-cancer mortality in a randomized European study.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Schröder FH, et al. N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18. N Engl J Med. 2009. PMID: 19297566 Free article. Clinical Trial.
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Roobol MJ, et al. Among authors: van leenders gl, van den bergh rc, van leeuwen pj. Eur Urol. 2010 Dec;58(6):893-9. doi: 10.1016/j.eururo.2010.09.030. Epub 2010 Sep 26. Eur Urol. 2010. PMID: 20933321 Clinical Trial.
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ. Zhu X, et al. Among authors: van leeuwen pj. Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.
225 results